Headquartered in Konstanz (Germany), LifeCodexx AG has been developing innovative and clinically validated non-invasive diagnostic tests based on the newest molecular analytical methods since 2010. With the PrenaTest®, Europe’s first non-invasive prenatal test (NIPT) for the determination of the most common chromosomal disorders in unborn children, launched in 2012, LifeCodexx AG has been changing prenatal diagnostics considerably. The test is performed in Germany and Switzerland in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices.
The PrenaTest® was completely developed in Konstanz (Germany) and is continuously being further developed there. Since its launch, our proprietary bioinformatics analysis software (PrenaTest® DAP.plus) has been CE marked. This is documenting that the software complies with the European IVD Directive with regard to product safety and medical-technical performance.
We cooperate with experienced laboratory service providers and providers of in-vitro diagnostics in many countries worldwide. They provide the PrenaTest® to qualified practices and clinics in the respective countries. Click here to find out in which countries the PrenaTest® is offered.